Shane Olwill's most recent trade in Pieris Pharmaceuticals Inc was a trade of 249,080 Stock Option (Right to buy) done . Disclosure was reported to the exchange on Feb. 24, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pieris Pharmaceuticals Inc | Shane Olwill | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 249,080 | 249,080 | - | - | Stock Option (Right to buy) | |
| Pieris Pharmaceuticals Inc | Shane Olwill | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 215,819 | 215,819 | - | - | Stock Option (Right to buy) | |
| Pieris Pharmaceuticals Inc | Shane Olwill | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 38,400 | 61,600 | - | - | Stock Option (right to buy) | |
| Pieris Pharmaceuticals Inc | Shane Olwill | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.52 per share. | 30 Aug 2021 | 38,400 | 43,038 (0%) | 0% | 1.5 | 58,368 | Common Stock |
| Pieris Pharmaceuticals Inc | Shane Olwill | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 5.15 per share. | 30 Aug 2021 | 29,200 | 4,638 (0%) | 0% | 5.2 | 150,380 | Common Stock |
| Pieris Pharmaceuticals Inc | Shane Olwill | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 30 Aug 2021 | 9,200 | 33,838 (0%) | 0% | 5 | 46,000 | Common Stock |